Cycloastragenol_product_DataBase

Bioactivity	Cycloastragenol (Astramembrangenin), the active form of astragaloside IV, has anti-oxidant, anti-inflammatory, anti-aging, anti-apoptotic, and cardiovascular protective effects. Cycloastragenol is a potent telomerase activator and can lengthen telomeres. Cycloastragenol alleviates age-related bone loss and improves bone microstructure and biomechanical properties[1][2][3].
Invitro	Cycloastragenol (0.03-3 μM; 24-72 hours) promotes viability, osteoblastic differentiation, and mineralization in MC3T3-E1 cells[3].
In Vivo	Cycloastragenol (5, 10, 20 mg/kg) is injected intraperitoneally at the onset of reperfusion, 12 h later and then twice daily for up to three days. Cycloastragenol dose-dependently reduces brain infarct volume, significantly ameliorated functional deficits, and prevents neuronal cell loss in middle cerebral artery occlusion (MCAO) mice. Cycloastragenol suppresses the mRNA expression of pro-inflammatory cytokines, including TNF-α and IL-1β, and inhibits the activation of microglia and astrocytes in the ischemic brain[2].
Name	Cycloastragenol
CAS	78574-94-4
Formula	C30H50O5
Molar Mass	490.72
Appearance	Solid
Transport	Room temperature in continental US; may vary elsewhere.
Storage	4°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Reference	[1]. Yu Y, et al. Cycloastragenol: An exciting novel candidate for age-associated diseases. Exp Ther Med. 2018;16(3):2175-2182. [2]. Li M, et al. Cycloastragenol upregulates SIRT1 expression, attenuates apoptosis and suppresses neuroinflammation after brain ischemia. Acta Pharmacol Sin. 2020;41(8):1025-1032. [3]. Yu Y, et al. Cycloastragenol prevents age-related bone loss: Evidence in d-galactose-treated and aged rats. Biomed Pharmacother. 2020;128:110304.

PeptideDB

Cycloastragenol

CAS: 78574-94-4 F: C30H50O5 W: 490.72